MarketIntelligenceCenter.com (Free subscription) | yesterday
GlaxoSmithKline PLC (NYSE: GSK) hit a new 52-Week high of $42.70 so far today. Currently the stock is up $1.12 (2.7%) to $42.65 on 852,101 shares traded. Today's high is up $15.50 from a 52-Week Low of $27.15. GlaxoSmithKline PLC stock has been showing support around $40.72 and resistance in the $41.96 range. Technic...
H5N1 (Free subscription) | 9 hours ago
Via Google News, an Associated Press story: GlaxoSmithKline pulls swine flu vaccines in Canada. Excerpt:Pharmaceuticals company GlaxoSmithKline PLC said Tuesday it has advised medical staff in Canada to not use one batch of swine flu vaccines in case they trigger...
San Fransisco Chronicle (Free subscription) | 8 hours ago
Canadian doctors have been advised not to use a batch of 170,000 swine flu vaccines after six reports of serious allergic reactions among recipients, but there are no similar reports from other countries, pharmaceuticals company GlaxoSmithKline PLC said... GlaxoSmithKline - Vaccine - Swine influenza - Allergy - Pharmaceutical drug
cryptogon.com (Free subscription) | 9 hours ago
Via: AP: Pharmaceuticals company GlaxoSmithKline PLC said Tuesday it has advised medical staff in Canada to not use one batch of swine flu vaccines in case they trigger life-threatening allergies. Company spokeswoman Gwenan White said that they issued the advice after reports that one batch of the swine flu vaccine might have caused more allergic reactions than [...]
Seattle Times (Free subscription) | 9 hours ago
Canadian doctors have been advised not to use a batch of 170,000 swine flu vaccines after six reports of serious allergic reactions among recipients, but there are no similar reports from other countries, pharmaceuticals company GlaxoSmithKline PLC said Tuesday.
Examiner (Free subscription) | 9 hours ago
Pharmaceuticals company GlaxoSmithKline PLC said Tuesday it has advised medical staff in Canada to not use one batch of swine flu vaccines in case they trigger life-threatening allergies.
USA Today (Free subscription) | 10 hours ago
Pharmaceuticals company GlaxoSmithKline PLC said Tuesday it has advised medical staff in Canada to not use one batch of swine ...
Gothamist (Free subscription) | 10 hours ago
Eep: 1010WINS reports , "Pharmaceuticals company GlaxoSmithKline PLC said Tuesday it has advised medical staff in Canada to not use one batch of swine flu vaccines in case they trigger life-threatening allergies. Company spokeswoman Gwenan White said that they issued the advice after reports that one batch of the swine flu vaccine might have caused more allergic reactions than normal." The...
The Huffington Post (Free subscription) | 10 hours ago
LONDON — Pharmaceuticals company GlaxoSmithKline PLC said Tuesday it has advised medical staff in Canada to not use one batch of swine flu vaccines in case they trigger life-threatening allergies. Company spokeswoman Gwenan White said that they issued the advice after reports that one batch of the swine flu vaccine might have caused more allergic reactions than normal. "We have advised health...
Miami Herald (Free subscription) | yesterday
British drugmaker GlaxoSmithKline PLC said Monday it is temporarily withdrawing its application for U.S. approval of a drug to prevent prostate cancer.
Rocky Mount Telegram - Business (Free subscription) | yesterday
TRENTON, N.J. — British drugmaker GlaxoSmithKline PLC said Monday it is temporarily withdrawin...
San Fransisco Chronicle (Free subscription) | yesterday
British drugmaker GlaxoSmithKline PLC says it's withdrawing its application for U.S. approval of a drug to prevent prostate cancer. The drug is already sold under the name Avodart, for treating symptoms of an enlarged prostate. The company was seeking... Cancer - Prostate cancer - Health - Conditions and Diseases - Prostate
Avian Flu Diary (Free subscription) | yesterday
# 4066 GlaxoSmithKline, makers of the Arepanrix vaccine, have ordered doctors to hold off giving any more doses from one particular batch while the company investigates a higher than normal number of allergic reactions. The number of doses on hold are about 170,000 – a fraction of the 7.5 million doses already delivered to Canada. Six cases of anaphylaxis from this batch were reported in Manitoba,...
Market Watch (Free subscription) | 18/11/2009
BOSTON (MarketWatch) -- Vivus Inc. early Wednesday reported positive Phase III clinical results for its new drug avanafil for the treatment of erectile dysfunction, or ED. "These Phase III avanafil data not only confirm the robust efficacy we've seen in earlier trials, but potentially differentiate avanafil from other PDE5 inhibitors when it comes to side effects and time-to-onset of efficacy,"...
Joseph Kim, MD, MPH (Free subscription) | 17/11/2009
The FDA approved the fifth vaccine for protection against the 2009 H1N1 influenza virus. The vaccine is manufactured by ID Biomedical Corp. of Quebec, Canada, owned by GlaxoSmithKline PLC. So, here's a list of the current injectable H1N1 vaccines: Influenza A (H1N1) 2009 Monovalent Vaccine (CSL Limited) Influenza A (H1N1) 2009 Monovalent Vaccine (ID Biomedical Corporation of Quebec) Influenza A (H1N1)...
Videos